Pharmacokinetics of amikacin in hematologic malignancies.

Por Kaojarern, S, Maoleekoonpairoj, S, Atichartakarn, V
Publicado em 1989

Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers.

Por Maoleekoonpairoj, S, Mittelman, A, Savona, S, Ahmed, T, Puccio, C, Gafney, E, Skelos, A, Arnold, P, Coombe, N, Baskind, P
Publicado em 1989

Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma

Por Guan, Z, Wang, Y, Maoleekoonpairoj, S, Chen, Z, Kim, W S, Ratanatharathorn, V, Reece, W H H, Kim, T W, Lehnert, M
Publicado em 2003